Two-year results of a treat-and-extend regimen with aflibercept for polypoidal choroidal vasculopathy
- 1 July 2017
- journal article
- retinal disorders
- Published by Springer Nature in Graefe's Archive for Clinical and Experimental Ophthalmology
- Vol. 255 (10) , 1891-1897
Abstract
To evaluate the effects of aflibercept therapy using a treat-and-extend regimen on treatment-naïve polypoidal choroidal vasculopathy (PCV).Keywords
This publication has 34 references indexed in Scilit:
- One-year outcomes of a treat-and-extend regimen of intravitreal aflibercept for polypoidal choroidal vasculopathyJapanese Journal of Ophthalmology, 2016
- Comparison of initial treatment between 3-monthly intravitreal aflibercept monotherapy and combined photodynamic therapy with single intravitreal aflibercept for polypoidal choroidal vasculopathyGraefe's Archive for Clinical and Experimental Ophthalmology, 2016
- Age-related macular degeneration and polypoidal choroidal vasculopathy in AsiansProgress in Retinal and Eye Research, 2016
- Short-term efficacy of intravitreal aflibercept for patients with treatment-naïve polypoidal choroidal vasculopathyGraefe's Archive for Clinical and Experimental Ophthalmology, 2014
- EVEREST STUDYRetina, 2012
- HORIZON: An Open-Label Extension Trial of Ranibizumab for Choroidal Neovascularization Secondary to Age-Related Macular DegenerationOphthalmology, 2012
- Subfoveal Retinal and Choroidal Thickness After Verteporfin Photodynamic Therapy for Polypoidal Choroidal VasculopathyAmerican Journal of Ophthalmology, 2011
- A Variable-dosing Regimen with Intravitreal Ranibizumab for Neovascular Age-related Macular Degeneration: Year 2 of the PrONTO StudyAmerican Journal of Ophthalmology, 2009
- Ranibizumab versus Verteporfin for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006
- [Criteria for diagnosis of polypoidal choroidal vasculopathy].2005